Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
- PMID: 36961024
- PMCID: PMC10037648
- DOI: 10.3390/pharmacy11020045
Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
Abstract
Long-acting injectable antipsychotics (LAIAs) have demonstrated positive outcomes for people with serious mental illnesses. They are underused, and access to LAIAs can be challenging. Pharmacies could serve as suitable environments for LAIA injection by pharmacists. To map and characterize the literature regarding the administration of LAIAs by pharmacists, a scoping review was conducted. Electronic-database searches (e.g., PsycINFO, Ovid Medline, Scopus, and Embase) and others including ProQuest Dissertations & Theses Global and Google, were conducted. Citation lists and cited-reference searches were completed. Zotero was used as the reference-management database. Covidence was used for overall review management. Two authors independently screened articles and performed full-text abstractions. From all sources, 292 studies were imported, and 124 duplicates were removed. After screening, 13 studies were included for abstraction. Most articles were published in the US since 2010. Seven studies used database and survey methods, with adherence and patient satisfaction as the main patient-outcomes assessed. Reporting of pharmacists' and patients' perspectives surrounding LAIA administration was minimal and largely anecdotal. Financial analyses for services were also limited. The published literature surrounding pharmacist administration of LAIAs is limited, providing little-to-no guidance for the development and implementation of this service by others.
Keywords: health services accessibility; injections; long-acting antipsychotic; pharmacist; review; scope of practice.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications.J Am Pharm Assoc (2003). 2023 May-Jun;63(3):742-750.e3. doi: 10.1016/j.japh.2022.08.006. Epub 2022 Aug 12. J Am Pharm Assoc (2003). 2023. PMID: 36740528
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy.J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4S):S24-S29.e2. doi: 10.1016/j.japh.2018.04.035. J Am Pharm Assoc (2003). 2018. PMID: 30006184
-
Medication-related issues associated with the documentation and administration of long-acting injectable antipsychotics.Int J Clin Pharm. 2019 Jun;41(3):623-629. doi: 10.1007/s11096-019-00814-6. Epub 2019 Apr 3. Int J Clin Pharm. 2019. PMID: 30945046 Review.
-
Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review.Ment Health Clin. 2025 Feb 3;15(1):17-24. doi: 10.9740/mhc.2025.02.017. eCollection 2025 Feb. Ment Health Clin. 2025. PMID: 39974754 Free PMC article. Review.
Cited by
-
Rural ambulatory care pharmacists providing in-clinic and home visit services improve adherence to long-acting injectable antipsychotics.Ment Health Clin. 2024 Jun 3;14(3):229-232. doi: 10.9740/mhc.2024.06.229. eCollection 2024 Jun. Ment Health Clin. 2024. PMID: 38835813 Free PMC article.
-
Preparing for pharmacy-based delivery of long-acting injectable antiretrovirals: a pre-implementation study.BMC Health Serv Res. 2025 Jun 5;25(1):808. doi: 10.1186/s12913-025-12971-8. BMC Health Serv Res. 2025. PMID: 40474134 Free PMC article.
-
Community Pharmacists' Role in Reducing the Incidence of Cardiometabolic Adverse Drug Events in Schizophrenia: Insights from Mental Health Professionals.Medicina (Kaunas). 2023 Nov 21;59(12):2052. doi: 10.3390/medicina59122052. Medicina (Kaunas). 2023. PMID: 38138155 Free PMC article.
References
-
- Marcus S.C., Zummo J., Pettit A.R., Stoddard J., Doshi J.A. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J. Manag. Care Spec. Pharm. 2015;21:754–768. doi: 10.18553/jmcp.2015.21.9.754. - DOI - PMC - PubMed
-
- Kishimoto T., Hagi K., Kurokawa S., Kane J.M., Correll C.U. Long-Acting Injectable versus Oral Antipsychotics for the Maintenance Treatment of Schizophrenia: A Systematic Review and Comparative Meta-Analysis of Randomised, Cohort, and Pre–Post Studies. Lancet Psychiatry. 2021;8:387–404. doi: 10.1016/S2215-0366(21)00039-0. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources